

## Demographic questions

2. Your full name: \*

3. Your email address for correspondence: \*

4. The country where you live (if your responses will focus on the EU as a whole, choose 'EU'): \*

EU

Austria

Belgium

Bulgaria

Croatia

Cyprus

Czech Republic

Denmark

Estonia

Finland

France

Germany

Greece

Hungary

Ireland

Italy

Latvia

Lithuania

Luxembourg

Malta

Netherlands

Poland

Portugal

Romania

Slovakia

Slovenia

Spain

Sweden

United Kingdom

Other, please specify

5. Is your organisation registered in the Transparency Register of the European Commission and the European

Parliament?\*

Yes

No

Not applicable

If you are not answering this questionnaire as an individual, please register in the [Transparency Register](#). If your organisation/institution responds without being registered, the Commission will consider its input as that of an individual and will publish it as such.

6. Please provide the name of your organisation:

7. How would you describe your main business activities or the activities of the organisation you represent?\*

Academic or research centre

Health care, hospital, health institution

Private company

NGO (non-governmental organisation)

Industrial or trade association

Consultancy

Other, please specify

Page 3

### Demographic questions (continued)

9. Please specify the type of your organisation:

International

National

Regional

Local

Other, please specify

Page 4

### Demographic questions (continued)

10. Please specify the type of your organisation:

Research performing organisation (public, non-academic)

Research performing organisation (private)

University (including teaching)

Other, please specify

### Demographic questions (continued)

11. Please specify the type of your organisation:

- Public
- Private
- University (including teaching)
- Other, please specify

### Demographic questions (continued)

12. Please specify size:

- Micro enterprise (<10 employees)
- Small enterprise (11-50 employees)
- Medium sized enterprise (51-250 employees)
- Large enterprise (>250 employees)

### Publication consent

13. We would like to ask whether you permit the EC to publish your reply. Do you consent to the publication of your reply?\*

- I consent to the publication of my reply, under the name supplied
- I consent to the publication of my reply, anonymously (no personal data included)
- I do not consent to the publication of my reply and I ask for the confidential treatment of my contribution (the contribution will not be published and its contents may not be taken into account. In any case, the contribution will be subject to the rules on access to documents, Regulation EC No 1049/2001)

### Familiarity with the EU Action Plan on Antimicrobial Resistance

14. How familiar are you with the EU's Action Plan against risks arising from antimicrobial resistance?\*

- Very familiar
- Somewhat familiar
- Not at all familiar
- Unsure / Do not know

15. Are you in a position to comment on the areas covered by the EU Action Plan with respect to the human or animal contexts? Your response to this question will determine whether you are offered questions on human health, animal health or both. Please choose the most appropriate answer based on your knowledge and experience.\*

Human

Animal

Both human and animal health

Unsure / Do not know

## Relevance

This section aims to assess the extent to which the original objectives of the EU Action Plan correspond to the current needs within the EU. It also addresses the extent to which the original objectives corresponded with EU needs when the Action Plan was developed in 2011.

15. The EU Action Plan against the rising threats from antimicrobial resistance was published in 2011. Its objectives correspond to the list below. Please rate how relevant each area was for the EU situation on antimicrobial resistance **when the Action Plan was established in 2011**.

	Very relevant	Somewhat relevant	Not relevant	Unsure / do not know
Appropriate use of antimicrobials in humans				
Prevention of microbial infections and their spread in humans				
Development of new effective antimicrobials for use in humans				
Development of alternatives for treatment of microbial infections for use in humans				
Cooperation at international level to contain the risk of antimicrobial resistance				
Cooperation at EU level to contain the risk of antimicrobial resistance				
Monitoring and surveillance of antimicrobial resistance in humans				
Monitoring and surveillance of antimicrobial use in humans				
Research into the causes of antimicrobial resistance				
Research on the prudent use of antimicrobials in humans and the impact of imprudent use				
Communication, education and training for human health professionals				
Communication, education and training				

for the general public

16. The EU Action Plan against the rising threats from antimicrobial resistance was published in 2011. Its objectives correspond to the list below. Please rate how relevant each area was for the EU situation on antimicrobial resistance **when the Action Plan was established in 2011**.

	Very relevant	Somewhat relevant	Not relevant	Unsure / do not know
Appropriate use of antimicrobials in animals				
Prevention of microbial infections and their spread in animals				
Development of new effective antimicrobials for use in animals				
Development of alternatives for treatment of microbial infections for use in animals				
Cooperation at international level to contain the risk of antimicrobial resistance				
Cooperation at EU level to contain the risk of antimicrobial resistance				
Monitoring and surveillance of antimicrobial resistance in animals				
Monitoring and surveillance of antimicrobial use in animals				
Research into the causes of antimicrobial resistance				
Research on the prudent use of antimicrobials in animals and the impact of imprudent use				
Communication, education and training for people caring for animals				
Communication, education and training for the general public				

17. The EU Action Plan against the rising threats from antimicrobial resistance was published in 2011. Its objectives correspond to the list below. Please rate how relevant each area was for the EU situation on antimicrobial resistance **when the Action Plan was established in 2011**.

	Very relevant	Somewhat relevant	Not relevant	Unsure / do not know
Appropriate use of antimicrobials in humans				

Appropriate use of antimicrobials in animals

Prevention of microbial infections and their spread in humans

Prevention of microbial infections and their spread in animals

Development of new effective antimicrobials

Development of alternatives for treatment of microbial infections

Cooperation at international level to contain the risk of antimicrobial resistance

Cooperation at EU level to contain the risk of antimicrobial resistance

Monitoring and surveillance of antimicrobial resistance

Monitoring and surveillance of antimicrobial use in human

Monitoring and surveillance of antimicrobial use in animals

Research into the causes of antimicrobial resistance

Research on the prudent use of antimicrobials and the impact of imprudent use

Communication, education and training for human health professionals

Communication, education and training for people caring for animals

Communication, education and training for the general public

### Relevance (continued)

18. Please rate how relevant each EU Action Plan objective is for the **current (2015) situation on antimicrobial resistance**.

	Very relevant	Somewhat relevant	Not relevant	Unsure / do not know
--	---------------	-------------------	--------------	----------------------

Appropriate use of antimicrobials in humans

Prevention of microbial infections and their spread in humans

Development of new effective antimicrobials for use in humans

Development of alternatives for treatment of microbial infections for use in humans

Cooperation at international level to contain the risk of antimicrobial resistance

Cooperation at EU level to contain the risk of antimicrobial resistance

Monitoring and surveillance of antimicrobial resistance in humans

Monitoring and surveillance of antimicrobial use in humans

Research into the causes of antimicrobial resistance

Research on the prudent use of antimicrobials in humans and the impact of imprudent use

Communication, education and training for human health professionals

Communication, education and training for the general public

19. Please rate how relevant each EU Action Plan objective is for the **current (2015) situation on antimicrobial resistance**.

	<b>Very relevant</b>	<b>Somewhat relevant</b>	<b>Not relevant</b>	<b>Unsure / do not know</b>
Appropriate use of antimicrobials in animals				
Prevention of microbial infections and their spread in animals				
Development of new effective antimicrobials for use in animals				
Development of alternatives for treatment of microbial infections for use in animals				
Cooperation at international level to contain the risk of antimicrobial resistance				
Cooperation at EU level to contain the risk of antimicrobial resistance				
Monitoring and surveillance of antimicrobial resistance in animals				
Monitoring and surveillance of				

antimicrobial use in animals

Research into the causes of antimicrobial resistance

Research on the prudent use of antimicrobials in animals and the impact of imprudent use

Communication, education and training for people caring for animals

Communication, education and training for the general public

20. Please rate how relevant each EU Action Plan objective is for the **current (2015) situation on antimicrobial resistance**.

	<b>Very relevant</b>	<b>Somewhat relevant</b>	<b>Not relevant</b>	<b>Unsure / do not know</b>
Appropriate use of antimicrobials in humans				
Appropriate use of antimicrobials in animals				
Prevention of microbial infections and their spread in humans				
Prevention of microbial infections and their spread in animals				
Development of new effective antimicrobials				
Development of alternatives for treatment of microbial infections				
Cooperation at international level to contain the risk of antimicrobial resistance				
Cooperation at EU level to contain the risk of antimicrobial resistance				
Monitoring and surveillance of antimicrobial resistance				
Monitoring and surveillance of antimicrobial use in human				
Monitoring and surveillance of antimicrobial use in animals				
Research into the causes of antimicrobial resistance				
Research on the prudent use of antimicrobials and the impact of imprudent use				
Communication, education and training				



for human health professionals

Communication, education and training

for people caring for animals

Communication, education and training

for the general public

**Relevance (continued)**

21. Are there any other important issues for addressing antimicrobial resistance not covered by the objectives listed above?

No, all of the important issues are covered

Yes

Unsure / Do not know

22. Do you expect some of these issues to become more important in the next 5-10 years than they are now?

Yes, all of these issues will become more important in 5-10 years

Yes, some of them will become more important in 5-10 years

No, I expect these issues to remain at the same level of importance as they are now

No, I expect these issues to decrease in importance in the next 5-10 years

Unsure / Do not know

23. If you would like to provide reasons for your answers to the question above, please do so here.

**Relevance (continued)**

24. Is the distribution of actions and responsibilities between the EU and Member States in the areas below appropriate? In an appropriate distribution, actions and responsibilities are in line with the competencies of the EU and Member States, with no areas being neglected and with no unnecessary duplication of effort.

Yes	No	Unsure / do not know
-----	----	-------------------------------

Appropriate use of antimicrobials in humans

Prevention of microbial infections and their spread in humans

Development of new effective antimicrobials for use in humans

Development of alternatives for treatment of microbial infections

for use in humans

Cooperation at international level to contain the risk of antimicrobial resistance

Cooperation at EU level to contain the risk of antimicrobial resistance

Monitoring and surveillance of antimicrobial resistance in humans

Monitoring and surveillance of antimicrobial use in humans

Research into the causes of antimicrobial resistance

Research on the prudent use of antimicrobials in humans and the impact of imprudent use

Communication, education and training for human health professionals

Communication, education and training for the general public

25. Is the distribution of actions and responsibilities between the EU and Member States in the areas below appropriate? In an appropriate distribution, actions and responsibilities are in line with the competencies of the EU and Member States, with no areas being neglected and with no unnecessary duplication of effort.

	Yes	No	Unsure / do not know
--	-----	----	----------------------

Appropriate use of antimicrobials in animals

Prevention of microbial infections and their spread in animals

Development of new effective antimicrobials for use in animals

Development of alternatives for treatment of microbial infections for use in animals

Cooperation at international level to contain the risk of antimicrobial resistance

Cooperation at EU level to contain the risk of antimicrobial resistance

Monitoring and surveillance of antimicrobial resistance in animals

Monitoring and surveillance of antimicrobial use in animals

Research into the causes of antimicrobial resistance

Research on the prudent use of antimicrobials in animals and the impact of imprudent use

Communication, education and training for people caring for animals

Communication, education and training for the general public

26. Is the distribution of actions and responsibilities between the EU and Member States in the areas below appropriate? In an appropriate distribution, actions and responsibilities are in line with the competencies of the EU and Member States, with no areas being neglected and with no unnecessary duplication of effort.

Unsure

	Yes	No	/ do not know
Appropriate use of antimicrobials in humans			
Appropriate use of antimicrobials in animals			
Prevention of microbial infections and their spread in humans			
Prevention of microbial infections and their spread in animals			
Development of new effective antimicrobials			
Development of alternatives for treatment of microbial infections			
Cooperation at international level to contain the risk of antimicrobial resistance			
Cooperation at EU level to contain the risk of antimicrobial resistance			
Monitoring and surveillance of antimicrobial resistance			
Monitoring and surveillance of antimicrobial use in human			
Monitoring and surveillance of antimicrobial use in animals			
Research into the causes of antimicrobial resistance			
Research on the prudent use of antimicrobials and the impact of imprudent use			
Communication, education and training for human health professionals			
Communication, education and training for people caring for animals			
Communication, education and training for the general public			

27. If you answered 'no' to any of the areas above, please give reasons for your answer.

## Effectiveness

This section aims to assess the extent to which the implementation of the actions in the EU Action Plan caused changes, either positive or negative, in the antimicrobial resistance situation. It also asks for your assessment of the extent to which the objectives of the EU Action Plan have been achieved, and where objectives have not been met, and what factors may have hindered their achievement. This section also aims to assess the extent to which factors influenced the efficiency with which the achievements observed were attained.

28. The Action Plan states that, because antimicrobial resistance can spread between humans and animals and cross borders, tackling antimicrobial resistance requires a holistic approach involving many different sectors (e.g. medicine, veterinary medicine, animal husbandry, agriculture, environment and trade). Do you agree with the

need for a holistic approach?\*

Yes

No

Unsure / do not know

Page 14

### Effectiveness - holistic approach (continued)

29. Does the EU Action Plan capture this holistic approach?\*

Yes

No

Unsure / do not know

Page 15

### Effectiveness - trends in use in humans

The following questions refer to the effectiveness of the EU Action Plan with regard to specific actions related to human health.

30. In the past four years (since 2011), what has been the trend in the total consumption of antimicrobials for use in humans in the country in which you live (or EU, if you are responding on behalf of an EU-level institution or organisation)?

Increase in the use of antimicrobials

Decrease in the use of antimicrobials

No change in the use of antimicrobials

Unsure / Do not know

Page 16

### Effectiveness - trends in use in humans (continued)

31. Can the trend in the total consumption of antimicrobials for use in humans be attributed, wholly or in part, to the EU Action Plan?

Yes

No

Unsure / Do not know

Page 17

### Effectiveness - trends in use in humans (continued)

32. In the past four years (since 2011), what do you think the trend has been in the appropriate use of antimicrobials in humans in the country in which you live? ('Appropriate use' refers to using antimicrobials only when necessary and in accordance with best practice. 'Inappropriate use' would be taking antimicrobials for the wrong reasons or incorrectly).

Increase in appropriate use of antimicrobials

Decrease in appropriate use of antimicrobials

No change in appropriate use of antimicrobials

Unsure / Do not know

Page 18

**Effectiveness - trends in use in humans (continued)**

33. Do you think the trend in the appropriate use of antimicrobials in humans can be attributed, wholly or in part, to the EU Action Plan?

Yes

No

Unsure / Do not know

Page 19

**Effectiveness - trends in resistance in humans**

34. In the past four years (since 2011), what has been the trend in country-level indicators of resistance in microorganisms of major public health importance (e.g. multidrug-resistant tuberculosis or multidrug-resistant *Salmonella*), including Hospital Acquired Infections (HAIs) in the country in which you live?

General improvement

Generally becoming worse

No change

Unsure / Do not know

Page 20

**Effectiveness - trends in human health (continued)**

35. In your assessment, can the trend in country-level indicators of resistance in microorganisms of major public health importance be attributed, wholly or in part, to the EU Action Plan?

Yes

No

Unsure / do not know

Page 21

**Effectiveness - prudent use in humans**

36. The EU Action Plan includes an action to ensure Member States effectively implement the [2002 Council Recommendations on the prudent use of antimicrobial agents in human medicines](#). The following set of questions refers to different aspects of this action. Please indicate whether in your assessment the following aspects of this recommendation have been achieved, partly achieved, or there has been no progress in the area in the past four years (since 2011) in the country in which you live (or the EU, if you are responding on behalf of an EU-level institution or organisation).

Unsure  
/ Do  
not  
know

Achieved

Partly  
achievedNo  
progressNot  
applicableImplementation of prescription-only  
requirements for antimicrobial agents

Implementation of control measures

against antimicrobial resistance in nursing homes and long-term care facilities

Development of education and training for healthcare workers on all aspects of antimicrobial resistance

Improvement in monitoring and assessment at national level of the implementation and efficiency of national strategies and control measures

37. In your assessment, can these developments be attributed (wholly or in part) to the EU Action Plan?

Yes

No

Unsure / Do not know

Page 22

### Effectiveness - developing new antimicrobials

The EU Action Plan includes an action to promote collaborative research and development efforts to bring new antibiotics to patients. The following questions refer to different aspects of this action. Please indicate whether in your assessment, the following aspects of the action have been achieved in the past four years (since 2011) in the country in which you live (or EU, if you are responding on behalf of an EU-level institution or organisation).

38. Improvement in efficiency of research and development through open sharing of knowledge (e.g. through the launch of a programme for research on new antibiotics with the European Federation of Pharmaceutical Industries and Associations within the Innovative Medicines Initiative Joint Undertaking).

Yes, this has been achieved

This has partly been achieved

There has been no progress in this area since 2011

Unsure / Do not know

Page 23

### Effectiveness - developing new antimicrobials (continued)

40. Can this development in open sharing of knowledge be attributed (wholly or in part), to the EU Action Plan?

Yes

No

Unsure / Do not know

Page 24

### Effectiveness - developing new antimicrobials (continued)

41. Establishment of adequate market and pricing conditions for new antibiotics.

Yes, this has been achieved

This has partly been achieved

There has been no progress in this area since 2011

Unsure / Do not know

Page 25

### Effectiveness - developing new antimicrobials (continued)

42. Can this development in the establishment of adequate market and pricing conditions for new antibiotics be attributed (wholly or in part), to the EU Action Plan?

Yes

No

Unsure / Do not know

Page 26

### Effectiveness - developing new antimicrobials (continued)

43. Implementing fast track procedures for the marketing authorisation of new antimicrobials in the country in which you live.

Yes, this has been achieved

This has partly been achieved

There has been no progress in this area since 2011

Unsure / Do not know

Page 27

### Effectiveness - developing new antimicrobials (continued)

44. Can this development in implementing fast track procedures for the marketing authorisation of new antimicrobials be attributed (wholly or in part), to the EU Action Plan?

Yes

No

Unsure / Do not know

Page 28

### Effectiveness - trends in use in animals

The following questions refer to the effectiveness of the EU Action Plan with regard to specific actions related to animal health.

45. In the past four years (since 2011), what has been the trend in the total consumption of antimicrobials for use in animals in the country in which you live (or EU, if you are responding on behalf of an EU-level institution or organisation)?

Increase in use of antimicrobials in animals

Decrease in use of antimicrobials in animals

No change

Unsure/ Do not know

Page 29

**Effectiveness - trends in use in animals (continued)**

46. In your assessment, can the trend in the total consumption of antimicrobials for use in animals be attributed, wholly or in part, to the EU Action Plan?

Yes

No

Unsure/ Do not know

Page 30

**Effectiveness - animal regulatory framework**

47. The EU Action Plan includes an action to strengthen the regulatory framework on veterinary medicines and medicated feed. Please indicate whether the following aspects of the action have been achieved, partly achieved or not achieved in the past four years (since 2011) in the country where you live (or the EU, if you are responding on behalf of an EU-level institution or organisation).

Unsure  
/ Do  
not  
know

Achieved

Partly  
achievedNot  
achieved

Appropriate warnings and guidance are provided on labels of veterinary antimicrobials

Restrictions have been considered on regular or off-label use of certain new or critically important antimicrobials for humans in the veterinary sector

Improvements to rules for advertisement of veterinary antimicrobials

Authorisation requirements sufficiently address risks and benefits of antimicrobial medicines

48. Can these developments be attributed wholly or in part to the EU Action Plan?

Yes

No

Unsure / Do not know

Page 31

**Effectiveness - prudent use in animals**

The EU Action Plan includes an action to introduce recommendations for prudent use of antimicrobials in veterinary medicine. These recommendations were published in September 2015 ([available on the European Commission's website](#)).

49. Are you familiar with the recommendations for prudent use of antimicrobials in veterinary medicine?



Yes

No

Unsure / Do not know

50. In your assessment, will the recommendations for prudent use of antimicrobials in veterinary medicine be effective in improving the prudent use of antimicrobials in veterinary medicine?

Yes

No

Unsure / Do not know

Page 32

### Effectiveness - need for new antimicrobials in animals

The EU Action Plan includes an action to promote efforts to analyse the need for new antibiotics in veterinary medicine. This includes a request for scientific advice to clarify whether the development of new veterinary antimicrobials would reduce antimicrobial resistance and the evaluation of the need for incentives that trigger development in veterinary medicines. Please consider whether these actions have been effective for tackling antimicrobial resistance in the EU.

52. First, has the request for scientific advice to clarify whether the development of new veterinary antimicrobials would reduce antimicrobial resistance been an effective step for tackling antimicrobial resistance in the EU?

Yes, it was an effective step

It was partly effective

No, it was not effective

Unsure / Do not know

53. Second, how does the current EU regulatory and market environment for veterinary medicines impact innovation in antimicrobials and related products?

Incentives exist that are effective in promoting innovation

There are insufficient incentives to promote innovation

Barriers discourage innovation in this area

Unsure / Do not know

Other, please explain

Page 33

### Effectiveness - research

55. The EU Action Plan includes an action on the reinforcement and coordination of research efforts. Please state whether the following aspects of this action have been effective, partly effective, or not effective for helping to tackle antimicrobial resistance in the EU or whether it is too early to say whether any findings from the research funded will be effective.

Effective	Partly effective	Not effective	Too early to	Unsure / Do not
-----------	------------------	---------------	--------------	-----------------

Promotion of further research aimed at better understanding antimicrobial resistance and pathogenic-host interactions

Promotion of further research on the development of diagnostic tools

Promotion of further research on the development of vaccines and other preventative strategies

Support of launch of a Joint Programming Initiative aimed at coordinating national research activities related to antimicrobial resistance

Support of launch of the Global Research Collaboration for Infectious Disease Preparedness (GLOPID-R)

56. If you would like to provide reasons for your answers to the question above, please do so here.

### Effectiveness - Animal Health Law

The EU Action Plan includes an action on the introduction of the new [Animal Health Law](#), which will focus on prevention of diseases, potentially reducing the use of antibiotics and replacing current animal health provisions for transmissible animal disease control.

57. Are you aware of the new EU Animal Health Law (agreed by the EP and Council on 1 June 2015, currently undergoing the procedure for adoption and publication)?

Yes

No

Unsure / Do not know

58. In your assessment, please indicate the potential effectiveness of the new EU Animal Health Law for tackling antimicrobial resistance:

High potential to be effective

Some potential to be effective

Little to no potential to be effective

Unsure / Do not know

59. In your assessment, please indicate the potential effectiveness of the inclusion of a legal basis for monitoring antimicrobial resistance in animal pathogens in the Commission's proposal for a new EU Animal Health Law.

- High potential to be effective
- Some potential to be effective
- Little to no potential to be effective
- Unsure / Do not know

Page 35

### Effectiveness - awareness

The following set of questions refers to efforts to improve awareness and education about antimicrobial resistance among the general public.

61. Has the country in which you live (or EU, if you are responding on behalf of an EU-level institution or organisation) implemented campaigns to improve awareness and/or education about antimicrobial resistance among the general public?

- Yes
- No
- Unsure / Do not know

Page 36

### Effectiveness - awareness (continued)

63. To what extent have these activities been effective?

- Very effective
- Somewhat effective
- Not effective
- Unsure / Do not know

64. Did either the EU Action Plan or other forms of EU support play a role in the decision to implement these activities?

- Yes, both the EU Action Plan and other forms of support
- Yes, other forms of support, but not the EU Action Plan
- No, neither the EU Action Plan nor other forms of EU support
- Unsure / Do not know

Page 37

### Effectiveness - bilateral and multilateral mechanisms

65. Are you aware of bilateral or multilateral mechanisms for preventing or controlling the spread of antimicrobial resistance? (examples include WHO EURO regional strategies, OIE health codes, Codex Alimentarius international standards, cooperation on reducing pollution by antimicrobial medicines in the environment, and the Transatlantic Taskforce on Antimicrobial Resistance (TATFAR))

- Yes
- No

Unsure / Do not know

Page 38

**Effectiveness - bilateral and multilateral mechanisms (continued)**

66. Can the existence of these bilateral or multilateral mechanisms for preventing or controlling the spread of antimicrobial resistance between the country in which you live and other countries or regions be attributed (wholly or in part) to the EU Action Plan?

Yes

No

Not applicable

Unsure / Do not know

67. Please explain whether the bilateral or multilateral mechanisms for preventing or controlling the spread of antimicrobial resistance that you refer to have been deepened or further developed as a result of the EU Action Plan.

Page 39

**Effectiveness - surveillance**

The next set of questions focus on monitoring and surveillance of antimicrobial resistance and the consumption of antimicrobials for public health.

68. The EU Action Plan includes an action on strengthening surveillance systems on antimicrobial resistance and antimicrobial consumption in animal medicine that has relevance for public health. In your assessment, please indicate the potential effectiveness of the following aspects of this action for helping to tackle antimicrobial resistance in the country in which you live (or the EU).

	<b>Effective</b>	<b>Partly effective</b>	<b>Not effective</b>	<b>Unsure / Do not know</b>
--	------------------	-------------------------	----------------------	-----------------------------

Reviews of the monitoring of antimicrobial resistance in zoonotic bacteria and indicator bacteria from humans, animals and food

With the support of the relevant EU agencies, establishment of harmonisation between human and veterinary surveillance to allow comparison of data

69. If you would like to provide reasons for your answers to the question above, please do so here.

**Effectiveness - human use surveillance**

71. Thinking about surveillance and monitoring of **antimicrobial use in humans** in the EU in the past four years (2011 onwards), what changes have occurred?

	Improved	Not changed	Became worse	Unsure / Do not know
Data coverage across EU Member States				
Harmonisation of data gathered across EU Member States				
Sustainability of surveillance				

72. Can these developments be attributed wholly or in part to the EU Action Plan?

Yes

No

Unsure / Do not know

**Effectiveness - human resistance surveillance**

73. Thinking about surveillance and monitoring of **antimicrobial resistance in humans** in the EU in the past four years (2011 onwards), what changes have occurred?

	Improved	Not changed	Became worse	Unsure / Do not know
Data coverage across EU Member States				
Harmonisation of data gathered across EU Member States				
Sustainability of surveillance				

74. Can these developments be attributed wholly or in part to the EU Action Plan?

Yes

No

Unsure / Do not know

### Effectiveness - surveillance in animals

The next set of questions focus on monitoring and surveillance of antimicrobial resistance and the consumption of antimicrobials for use in animals.

75. The EU Action Plan includes an action on strengthening surveillance systems on antimicrobial resistance and antimicrobial consumption in animal medicine that has relevance for public health. In your assessment, please indicate the potential effectiveness of the following aspects of this action for helping to tackle antimicrobial resistance in the country in which you live (or EU, if you are responding on behalf of an EU-level institution or organisation).

	Effective	Partly effective	Not effective	Unsure / Do not know
Reviews of the monitoring of antimicrobial resistance in zoonotic bacteria and indicator bacteria from humans, animals and food				
With the support of the relevant EU agencies, establishment of harmonisation between human and veterinary surveillance to allow comparison of data				

76. If you would like to provide reasons for your answers to the question above, please do so here.

### Effectiveness - animal use surveillance

78. Thinking about surveillance and monitoring of **antimicrobial use in animals** in the EU in the past four years (2011 onwards), what changes have occurred?

	Improved	Not changed	Became worse	Unsure / Do not know
Data coverage across EU Member States				
Harmonisation of data gathered across EU Member States				
Sustainability of surveillance				

79. Can these developments be attributed wholly or in part to the EU Action Plan?

Yes

No

Unsure / Do not know

Page 44

**Effectiveness - animal resistance surveillance**

80. Thinking about surveillance and monitoring of **antimicrobial resistance in animals** in the EU in the past four years (2011 onwards), what changes have occurred?

	Improved	Not changed	Became worse	Unsure / Do not know
Data coverage across EU Member States				
Harmonisation of data gathered across EU Member States				
Sustainability of surveillance				

81. Can these developments be attributed wholly or in part to the EU Action Plan?

Yes

No

Unsure / Do not know

Page 45

**Efficiency**

This section aims to help assess whether available EU funding has been used efficiently.

82. EU funds have been spent on several interventions related to antimicrobial resistance, including interventions aimed at improving knowledge of antimicrobial resistance, promoting research on antimicrobial resistance, and implementing harmonised surveillance of antimicrobial resistance in animals and food. Which areas, in your assessment, should have highest priority to receive financial support from the EU?

	High priority	Medium priority	Low priority	Unsure / do not know
Appropriate use of antimicrobials in humans				
Prevention of microbial infections and their spread in humans				
Development of new effective antimicrobials for use in humans				
Development of alternatives for treatment of microbial infections for use in humans				

Cooperation at international level to contain the risk of antimicrobial resistance

Cooperation at EU level to contain the risk of antimicrobial resistance

Monitoring and surveillance of antimicrobial resistance in humans

Monitoring and surveillance of antimicrobial use in humans

Research into the causes of antimicrobial resistance

Research on the prudent use of antimicrobials in humans and the impact of imprudent use

Communication, education and training for human health professionals

Communication, education and training for the general public

83. EU funds have been spent on several interventions related to antimicrobial resistance, including interventions aimed at improving knowledge of antimicrobial resistance, promoting research on antimicrobial resistance, and implementing harmonised surveillance of antimicrobial resistance in animals and food. Which areas, in your assessment, should have highest priority to receive financial support from the EU?

	<b>High priority</b>	<b>Medium priority</b>	<b>Low priority</b>	<b>Unsure / do not know</b>
Appropriate use of antimicrobials in animals				
Prevention of microbial infections and their spread in animals				
Development of new effective antimicrobials for use in animals				
Development of alternatives for treatment of microbial infections for use in animals				
Cooperation at international level to contain the risk of antimicrobial resistance				
Cooperation at EU level to contain the risk of antimicrobial resistance				
Monitoring and surveillance of antimicrobial resistance in animals				
Monitoring and surveillance of antimicrobial use in animals				
Research into the causes of antimicrobial resistance				



Research on the prudent use of antimicrobials in animals and the impact of imprudent use

Communication, education and training for people caring for animals

Communication, education and training for the general public

84. EU funds have been spent on several interventions related to antimicrobial resistance, including interventions aimed at improving knowledge of antimicrobial resistance, promoting research on antimicrobial resistance, and implementing harmonised surveillance of antimicrobial resistance in animals and food. Which areas, in your assessment, should have highest priority to receive financial support from the EU?

	<b>High priority</b>	<b>Medium priority</b>	<b>Low priority</b>	<b>Unsure / do not know</b>
Appropriate use of antimicrobials in humans				
Appropriate use of antimicrobials in animals				
Prevention of microbial infections and their spread in humans				
Prevention of microbial infections and their spread in animals				
Development of new effective antimicrobials				
Development of alternatives for treatment of microbial infections				
Cooperation at international level to contain the risk of antimicrobial resistance				
Cooperation at EU level to contain the risk of antimicrobial resistance				
Monitoring and surveillance of antimicrobial resistance				
Monitoring and surveillance of antimicrobial use in human				
Monitoring and surveillance of antimicrobial use in animals				
Research into the causes of antimicrobial resistance				
Research on the prudent use of antimicrobials and the impact of imprudent use				
Communication, education and training for human health professionals				

Communication, education and training  
for people caring for animals

Communication, education and training  
for the general public

85. Are you aware of any ways in which the allocation of EU spending on AMR has been inappropriate or inefficient? Inappropriate and inefficient spending would include spending on unnecessary activities, spending on areas that may be of a lower priority than others that did not receive funding, and spending on activities that are unlikely to help EU efforts to tackle AMR.

Yes

No

86. Do you have any further comments on EU funding?

**Page 46**

### **Coherence**

This section aims to assess the extent to which the Action Plan on AMR works in line with Member States and international interventions, plans or strategies which have similar objectives and EU policies and activities in other areas.

87. Are you aware of any ways that the EU and Member State governments are coordinating their activities for tackling antimicrobial resistance?\*

Yes

No

**Page 47**

### **Coherence (continued)**

88. How effective are these coordination efforts?

Very effective

Somewhat effective

Not very effective

Not effective at all

Unsure / do not know

89. If you would like to provide reasons for your answers to the question above, please do so here.

**Coherence (continued)**

90. Do you agree with the following statement? The EU Action Plan complement and/or reinforce existing EU policies in the following areas.

	<b>Strongly agree</b>	<b>Agree</b>	<b>Disagree</b>	<b>Strongly disagree</b>	<b>Unsure / do not know</b>
Environment					
Human health					
Animal health and welfare					
Food safety					
Agriculture					
Research					
Competitiveness					
SMEs					

91. If you would like to provide reasons for your answers to the question above, please do so here.

**Coherence (continued)**

92. Are you aware of actions at international level for tackling antimicrobial resistance undertaken by the entities listed below?

	<b>Yes</b>	<b>No</b>
Non-EU OECD countries (e.g. Switzerland, Norway, USA, Canada)		
Transatlantic Task Force on antimicrobial resistance (TATFAR)		
World Health Organization (WHO)		
World Organisation for Animal Health (OIE)		
Food and Agriculture Organization of the United Nations (UN)		

FAO)

Other, please specify

93. Please identify any other international organisations active in the fight against antimicrobial resistance.

Page 50

### Coherence (continued)

94. Do you think these actions are coordinated well with Member States in the EU?

Yes

No

Unsure / do not know

Page 51

### Added value

This section aims to assess the added value of the EU Action Plan on antimicrobial resistance compared to what could be achieved by EU Member States at national and/or regional levels.

95. Do you agree with the following statement? The EU Action Plan identifies actions best dealt with at EU level.

Strongly Agree

Agree

Disagree

Strongly Disagree

Unsure / Do not know

96. If you would like to give reasons for your answer, please do so here.

Page 52

### Added value (continued)

97. Do you agree with the following statement? Overall, the EU Action Plan has helped bring about improvements in

the situation on antimicrobial resistance in the EU that would not have happened otherwise.

Strongly Agree

Agree

Disagree

Strongly Disagree

Unsure / Do not know

98. Are you aware of activities related to tackling AMR in the country in which you live that were enabled by EU funds and would not have occurred without EU funding (or would have occurred more slowly or to a lesser extent)?

Yes

No

Not applicable

Unsure / Do not know

99. If you would like to provide reasons for your answers to the question above, please do so here.

### Closing question

100. Are there any further comments you would like to make?